$EPAZ The Street Reports: Guide to Penny Stocks Look Now!

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
131
$EPAZ The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ
Penny stocks attract considerable attention, but the more potent trick for investors to hunt for those stocks is by watching the trading activity. This feature would provide you with a closer look into penny stocks, which have been active over the past few days. Here is a look at four of those.

Clean Vision Corporation (OTC: CLNV): The company is one of the major innovators in the clean technology space, and on October 11, it announced that it had entered into a strategic agreement with Grant Thornton International. In its news release, Clean Vision Corporation noted that Grant Thornton was a leading worldwide advisory firm and would help it in issuing a maximum of $340 million in the form of green bonds.

The net proceeds from the issuance of the green bonds would be used by the company to form and operate the Plastic Conversion Network (PCN) under the Clean Seas umbrella across the world. The company further noted that the engagement with Grant Thornton was a major step towards the deployment of the PCN.

Another significant announcement from Clean Vision came about on September 7, when it revealed that the $1.75 million forgivable loan had been disbursed to it. The loan was pertaining to the Memorandum of Agreement that it had inked with the West Virginia Department of Economic Development. The company entered into the agreement on June 1, 2023. For the loan to be forgiven, the company would have to employ 40 people in a period of three years. The financing, which is non-dilutive in nature, would be used to fund the development of its Quincy, West Virginia-based plastic waste to circular waste facility.

Aravive Inc. (NASDAQ: ARAV) is a late-stage clinical company involved in the development of targeted therapeutics for treating metastatic disease. On October 17, the Aravive Inc. stock came into considerable focus and clocked gains of 62% amidst significant action.

On August 2, the company announced the Phase 3 AXLerate-OC trial for the purpose of evaluating the efficacy and safety of batiraxcept in platinum-resistant ovarian cancer. Aravive announced that the product failed to hit the primary endpoint of PFS (progression-free survival) in the subset of patients who had not been subjected to bevacizumab treatment previously. Additionally, it was noted at the time that the trial did not reveal any difference amongst the two different arms of the population, inclusive of patients who had been treated with bevacizumab in the past. At the time, Aravive announced that it would continue to evaluate the entirety of the dataset and come to a decision about the next steps.

RedHill Biopharma Ltd. (NASDAQ: RDHL) The specialty biopharmaceutical company made a key announcement about its product, opaganib, on October 3. RedHill Biopharma Ltd. announced that its unique twice-daily oral product recorded a statistically significant rise in survival time in an in vivo Ebola study conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

The product was administered in two doses of 150 mg/kg daily. It was the first ever host-directed molecule that had managed to show activity in combating the Ebola virus disease. The study by the United States Army tested three doses of opaganib-50, 100, and 150 mg/kg BID-against an inactive vehicle control arm. The results showed a mean survival time of 11.2 days following 150 mg/kg doses as opposed to a mean survival time of 5.5 days in the inactive vehicle control group. Previously, the product had also shown antiviral benefits for patients suffering from moderate to severe symptoms of COVID-19 infection.

Athersys Inc. (NASDAQ: ATHX) The cell therapy and regenerative medicine firm is involved in the development of MultiStem for critical care. On October 16, Athersys Inc. announced that it had gone into a warrant exercise inducement offer letter by way of which it would raise gross proceeds to the tune of $3.9 million. It would do so through the exercise of 28124590 warrants. Additionally, the company also got the first tranche of a $1.5 million payment from Helios KK as per the provisions of the global license for acute respiratory syndrome.

The company announced that it entered into the warrant exercise inducement offer letter on October 11 with an existing warrant holder. The transaction was closed on October 16. It was also noted in the news release that Athersys engaged the services of Alliance Global Partners as its financial advisor for the transaction.

Epazz Inc. (OTC: EPAZ): The cloud-based software leader is a specialist in providing made-to-order cloud applications to corporations, public sector entities, and institutions of higher learning. Epazz Inc. also offers Epazz BoxesOS V3.0, which is described as a comprehensive web-based business software package for small to mid-sized businesses, governmental agencies, Fortune 500 companies, and higher education institutions.

On October 3, the company announced that its holding company, ZenaDrone, would send its first drones to Ireland. The drones had been at its new manufacturing plant. The shipment would comprise the first set of 20 ZenaDrone 1000s, which would help in the establishment of drone as a service (DaaS) operations in Ireland.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact

Company Name: The Street Reports

Contact Person: Editor

Email: editor@thestreetreports.com

Country: United States

Website: http://www.thestreetreports.com

Source: www.abnewswire.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 260

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 256

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 68

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 194

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 20

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 277

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 127

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading

Top 5 Most Recently Viewed Articles

Music Licensing, Inc. Enhances Transparency with Auditing Plans

Updated Category News Views 136

Pro Music Rights Embarks on a New Financial Journey In an important move towards greater accountability, Music Licensing, Inc. (OTC: SONG), also recognized as Pro Music Rights, has announced its intention to hire a PCAOB-registered audit firm to perform annual audits. This step reflects the company's dedication to enhancing the integrity of its financial reporting and...

Continue Reading
The Importance of Foreign Investment in China's Growth Strategy

Updated Category News Views 200

The Importance of Foreign Investment in China's Growth Strategy Foreign investment plays a pivotal role in shaping China’s robust economic landscape, a sentiment echoed by a growing number of experts and stakeholders. A recent wave of inquiries about the necessity of foreign investment for China's ongoing development highlights this matter as a crucial topic. This...

Continue Reading
CityBee Expands Operations with Major Lease Extensions

Updated Category News Views 313

Significant Lease Extensions for CityBee at Cuprum CityBee, a prominent joint venture in the UK office sector, has recently achieved a significant milestone by securing two critical lease extensions at Cuprum. This exciting development, involving major tenants, highlights when the future of office spaces is considered, the increasing demand for high-quality and...

Continue Reading
Exploring the Future of Geospatial Solutions in Key Industries

Updated Category News Views 319

Geospatial Solutions: A Market on the Rise The global geospatial solution market is gearing up for remarkable growth, estimated to reach approximately USD 545.7 billion soon and surpassing an impressive USD 2,061.3 billion in the coming years. This upward trajectory represents a compound annual growth rate (CAGR) of 14.2% projected between now and 2035, showcasing a...

Continue Reading
Progyny's Challenges and Insights into Fertility Benefits Landscape

Updated Category News Views 100

Progyny got rocked back in 2024 when news broke that Amazon ditched them for Maven Clinic's fertility benefits. You could feel the desks shuddering as this big player made its move, shaking up the entire landscape. This shift was like a punch to the gut for Progyny, especially since Amazon had been a key client. That loss wasn’t just some random hit; it was a direct...

Continue Reading